A Study of Pertuzumab in Participants With Metastatic Breast Cancer
Status:
Completed
Trial end date:
2005-04-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of pertuzumab (rhuMAb 2C4) in participants
with metastatic breast cancer which has progressed during or after standard chemotherapy and
which is not amenable to curative therapy. Those who are maintaining a response to therapy or
who have stable disease at the end of the formal study period will continue treatment until
disease progression or unacceptable toxicity. Approximately 120 participants will be
enrolled.